Review article: predicting response in hepatitis C virus therapy

被引:50
作者
Mihm, U [1 ]
Herrmann, E [1 ]
Sarrazin, C [1 ]
Zeuzem, S [1 ]
机构
[1] Univ Saarland, Dept Internal Med 2, Homburg, Germany
关键词
D O I
10.1111/j.1365-2036.2006.02863.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The introduction of combination therapy with ribavirin and of pegylated interferons has improved treatment results in patients with chronic hepatitis C. However, overall rates of sustained virologic response following antiviral therapy of chronic hepatitis C still do not exceed 54-63%. Because of several virus- and patient-related factors, treatment is even less successful in some patient subpopulations. The major viral factors associated with impaired response are hepatitis C virus genotype 1 infection and a high viral load. Among patient-related factors cirrhosis is of special importance. Baseline predictive factors for sustained virologic response become less important for prediction of treatment outcome when quantifications of hepatitis C virus RNA during early therapy are taken into account. This article provides a summary of virus- and patient-related parameters, which are prognostic for response to antiviral therapy in chronic hepatitis C and focuses on the prediction of treatment response by quantification of hepatitis C virus RNA concentration during therapy.
引用
收藏
页码:1043 / 1054
页数:12
相关论文
共 69 条
[11]   Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. [J].
Fried, MW ;
Shiffman, ML ;
Reddy, KR ;
Smith, C ;
Marinos, G ;
Goncales, FL ;
Haussinger, D ;
Diago, M ;
Carosi, G ;
Dhumeaux, D ;
Craxi, A ;
Lin, A ;
Hoffman, J ;
Yu, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13) :975-982
[12]   Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C -: A randomized study of treatment duration and ribavirin dose [J].
Hadziyannis, SJ ;
Sette, H ;
Morgan, TR ;
Balan, V ;
Diago, M ;
Marcellin, P ;
Ramadori, G ;
Bodenheimer, H ;
Bernstein, D ;
Rizzetto, M ;
Zeuzem, S ;
Pockros, PJ ;
Lin, A ;
Ackrill, AM .
ANNALS OF INTERNAL MEDICINE, 2004, 140 (05) :346-355
[13]   Slow viral dynamics of hepatitis C virus genotype 4 [J].
Halfon, P ;
Neumann, AU ;
Bourlière, M ;
Rieu, A ;
Chadapaud, S ;
Khiri, H ;
Ouzan, D .
JOURNAL OF VIRAL HEPATITIS, 2003, 10 (05) :351-353
[14]   Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis [J].
Heathcote, EJ ;
Shiffman, ML ;
Cooksley, WGE ;
Dusheiko, GM ;
Lee, SS ;
Balart, L ;
Reindollar, R ;
Reddy, RK ;
Wright, TL ;
Lin, A ;
Hoffman, J ;
De Pamphilis, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (23) :1673-1680
[15]   Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon [J].
Herrmann, E ;
Lee, JH ;
Marinos, G ;
Modi, M ;
Zeuzem, S .
HEPATOLOGY, 2003, 37 (06) :1351-1358
[16]  
HERRMANN E, 2005, HEPATOL REV, V2, P49
[17]   Hepatic steatosis in chronic hepatitis C virus infection: Prevalence and clinical correlation [J].
Hwang, SJ ;
Luo, JC ;
Chu, CW ;
Lai, CR ;
Lu, CL ;
Tsay, SH ;
Wu, JC ;
Chang, FY ;
Lee, SD .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2001, 16 (02) :190-195
[18]   Racial differences in the relationship between hepatitis C infection and iron stores [J].
Ioannou, GN ;
Dominitz, JA ;
Weiss, NS ;
Heagerty, PJ ;
Kowdley, KV .
HEPATOLOGY, 2003, 37 (04) :795-801
[19]   Peginterferon Alfa-2a (40 kd) and ribavirin for Black American patients with chronic HCV genotype 1 [J].
Jeffers, LJ ;
Cassidy, W ;
Howell, CD ;
Hu, S ;
Reddy, KR .
HEPATOLOGY, 2004, 39 (06) :1702-1708
[20]   Early viral kinetics on treatment with pegylated interferon-α-2a in chronic hepatitis C virus genotype 1 infection [J].
Jessner, W ;
Stauber, R ;
Hackl, F ;
Datz, C ;
Watkins-Riedel, T ;
Hofer, H ;
Gangl, A ;
Kessler, H ;
Ferenci, P .
JOURNAL OF VIRAL HEPATITIS, 2003, 10 (01) :37-42